KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Share-based Compensation (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Share-based Compensation for 16 consecutive years, with $79.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Share-based Compensation rose 29.51% year-over-year to $79.0 million, compared with a TTM value of $301.0 million through Dec 2024, up 8.27%, and an annual FY2025 reading of $310.0 million, up 2.99% over the prior year.
  • Share-based Compensation was $79.0 million for Q4 2024 at Thermo Fisher Scientific, up from $68.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $84.0 million in Q2 2024 and bottomed at $46.0 million in Q1 2020.
  • Average Share-based Compensation over 5 years is $65.6 million, with a median of $69.0 million recorded in 2024.
  • The sharpest move saw Share-based Compensation soared 52.94% in 2022, then fell 18.67% in 2023.
  • Year by year, Share-based Compensation stood at $51.0 million in 2020, then surged by 50.98% to $77.0 million in 2021, then decreased by 2.6% to $75.0 million in 2022, then dropped by 18.67% to $61.0 million in 2023, then rose by 29.51% to $79.0 million in 2024.
  • Business Quant data shows Share-based Compensation for TMO at $79.0 million in Q4 2024, $68.0 million in Q3 2024, and $84.0 million in Q2 2024.